menu
    • menu
    [{"orgOrder":0,"company":"DIMERx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"DMX-101","moa":"Kappa\/Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"DIMERx","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"DIMERx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"DIMERx \/ National Institute on Drug Abuse"}]

    Find Clinical Drug Pipeline Developments & Deals by DIMERx

    Menu

    DIMERx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            DIMERx

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            DIMERx

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DMX-101

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : $15.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            DIMERx Awarded Up to $15M by NIDA to Advance DMX-101 as Oral Therapy for Chronic Pain

                            Details : The funding will be used to advance its lead drug candidate, DMX-101, a novel, peripherally acting buprenorphine dimer with analgesic and anti-hyperalgesic properties, for chronic lower back pain.

                            Product Name : DMX-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 25, 2025

                            Lead Product(s) : DMX-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : $15.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth